August 25, 2026 August 25, 2026Categories Coming SoonNow Enrolling: EAA232 for Patients With Relapsed or Refractory High-Risk Multiple MyelomaThis trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment
![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
